Myocardial Protection in Combined Mitral-Aortic-Tricuspid Valve Diseases Correction under Cardiopulmonary Bypass

DOI: https://doi.org/10.30702/ujcvs/24.32(04)/GP066-9195
Keywords: antegrade, retrograde crystalloid cardioplegia, mitral and aortic valve replacement, tricuspid valve repair, mitral valve repair

Abstract

The aim. To determine the optimal option for administering cardioplegic solution for myocardial protection in the correction of combined mitral-aortic-tricuspid valve diseases (CMAT) under cardiopulmonary bypass.

Materials and methods. We analyzed the results of surgical treatment of 251 patients with CMAT who were operated on at the National Amosov Institute of Cardiovascular Surgery from 01/01/2010 to 01/01/2023 and in whom 3 ways of applying crystalloid cardioplegic solution was used. There were three comparison groups: group A with antegrade (n = 47), group B with retrograde (n = 56), and group C with combined ante-retrograde administration of crystalloid cardioplegic solution (n = 148).

Results. Of the 251 operated patients, 10 died at the hospital stage (mortality rate 3.9%). The level of creatine kinase-MB (CK-MB) (U/L) at cross-clamping time ≤90 minutes for the groups was as follows: 72.3 ± 7.1 (p < 0.05) in group A, 64.0 ± 8.2 in group B, 67.5 ± 7.7 in group C. The level of CK-MB (U/L) at cross-clamping time ≥151 minutes for the groups was as follows: 115.2 ± 18.7 in group A, 97.4 ± 15.8 in group B, 96.3 ± 16.2 in group C. The dynamics of echocardiographic parameters at the stages of treatment were as follows. Group A (mortality rate 4.3%): left ventricular (LV) end-systolic index (mL/m2): 69.1 ± 13.5 (before surgery), 60.3 ± 9.7 (after surgery); left ventricular ejection fraction (LVEF): 51% ± 9% (before surgery), 54% ± 7% (after surgery). Group B (mortality rate 3.6%): LV end-systolic index (mL/m2) 66.5 ± 12.1 (before surgery), 57.4 ± 8.6 (after surgery); LVEF: 50% ± 8% (before surgery), 56% ± 7% (after surgery). Group C (mortality rate 4.1%): LV end-systolic index (mL/m2) 67.8 ± 11.3 (before surgery), 56.2 ± 8.9 (after surgery); LVEF: 50% ± 7% (before surgery), 56% ± 7% (after surgery). The dynamics of echocardiographic parameters at the stages of treatment were better in groups B and C than in group A (p < 0.05). Hospital mortality was lower in groups B and C than in group A (p > 0.05).

Conclusions. The three types of cardioplegic solution delivery used in complex pathology of surgical treatment of CMAT demonstrated the adequacy of heart protection using crystalloid cardioplegia. Taking into account certain advantages in the dynamics of restoration of the LV contractility and increase in the level of CK-MB (U/L) on the second day after surgery, groups C and B should be considered optimal compared to group A (p < 0.05). The widespread, branched venous system of the heart allows for adequate use of the retrograde route of cardioplegia delivery and complete penetration of cardioplegic solution into the heart cells, which provides a better clinical effect compared to the isolated antegrade route of crystalloid cardioplegia delivery.

References

  1. Pagni S, Ganzel BL, Singh R, Austin EH, Mascio C, Williams ML, et al. Clinical Outcome After Triple-Valve Operations in the Modern Era: Are Elderly Patients at Increased Surgical Risk? Ann Thorac Surg.2014;97(2):569-576. https://doi.org/10.1016/j.athoracsur.2013.07.083
  2. Leone A, Fortuna D, Gabbieri D, Nicolini F, Contini GA, Pigini F, et al.; RERIC (Emilia Romagna Cardiac Surgery Registry) Investigators. Triple valve surgery: results from a multicenter experience. J Cardiovasc Med (Hagerstown). 2018;19(7):382-388. https://doi.org/10.2459/JCM.0000000000000665
  3. Davarpasand T, Hosseinsabet A. Triple valve replacement for rheumatic heart disease: short- and mid-term survival in modern era. Interact Cardiovasc Thorac Surg. 2015;20(3):359-364. https://doi.org/10.1093/icvts/ivu400
  4. Shan Y, Xie K, Zhou Q, He R, Chen Z, Feng W. Sevoflurane alleviates myocardial ischemia/reperfusion injury via actitation of heat shock protein-70 in patients undergoing double valve replacement surgery. Am J Transl Res. 2022;14(8):5529-5540. PubMed PMID: 36105042.
  5. Lam VT, Kinh NQ, Ly NM. Cardioprotective Efficacy of Sevoflurane in Patients With Rheumatic Heart Disease Undergoing Heart Valve Surgery Under Cardiopulmonary Bypass. J Saudi Heart Assoc. 2024;36(2):120-127. https://doi.org/10.37616/2212-5043.1384
  6. Pesonen E, Vlasov H, Suojaranta R, Hiippala S, Schramko A, Wilkman E, et al. Effect of 4% Albumin Solution vs Ringer Acetate on Major Adverse Events in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Randomized Clinical Trial. JAMA. 2022;328(3):251-258. https://doi.org/10.1001/jama.2022.10461
  7. Numaguchi R, Takaki J, Nishigawa K, Yoshinaga T, Fukui T. Outcomes of mitral valve replacement with complete annular decalcification. Asian Cardiovasc Thorac Ann. 2023;31(9):775-780. https://doi.org/10.1177/02184923231206237
  8. Li G, Li P, Liu S, You B. Follow-Up of Robotic Mitral Valve Repair: A Single Tertiary Institution Experience in China. Comput Math Methods Med. 2022;2022:1997371. https://doi.org/10.1155/2022/1997371
  9. Musumeci F, Lio A, Montalto A, Bergonzini M, Cammardella AG, Comisso M, et al. Minimally invasive treatment of multiple valve disease: A modified approach through a right lateral minithoracotomy. J Card Surg. 2020;35(1):135-139. https://doi.org/10.1111/jocs.14339
  10. Kowalewski M, Pasierski M, Finke J, Kołodziejczak M, Staromłyński J, Litwinowicz R, et al.; Thoracic Research Centre. Permanent pacemaker implantation after valve and arrhythmia surgery in patients with preoperative atrial fibrillation. Heart Rhythm. 2022;19(9):1442-1449. https://doi.org/10.1016/j.hrthm.2022.04.007
  11. Baysal A, Sagiroglu G, Dogukan M, Ozkaynak I. Investigation of Risk Factors Related to the Development of Hepatic Dysfunction in Patients with a Low and Moderate Cardiac Risk During Open-Heart Surgeries. Braz J Cardiovasc Surg. 2021;36(2):219-228. https://doi.org/10.21470/1678-9741-2019-0427
  12. Salsano A, Giacobbe DR, Del Puente F, Natali R, Miette A, Moscatelli S, et al. Culture-negative infective endocarditis (CNIE): impact on postoperative mortality. Open Med (Wars). 2020;15(1):571-579. https://doi.org/10.1515/med-2020-0193
  13. Lio A, Murzi M, Di Stefano G, Miceli A, Kallushi E, Ferrarini M, et al. Triple valve surgery in the modern era: short- and long-term results from a single centre. Interact Cardiovasc Thorac Surg. 2014;19(6):978-984. https://doi.org/10.1093/icvts/ivu273
  14. Shimamura J, Okumura K, Misawa R, Bodin R, Nishida S, Tavolacci S, et al. Strategy and Outcomes of Cardiac Surgery in Patients With Cirrhosis: Comprehensive Approach With Liver Transplant Program. Clin Transplant. 2024;38(9):e15451. https://doi.org/10.1111/ctr.15451
  15. Malhotra A, Wadhawa V, Ramani J, Garg P, Sharma P, Pandya H, et al. Normokalemic nondepolarizing long-acting blood cardioplegia. Asian Cardiovasc Thorac Ann. 2017;25(7-8):495-501. https://doi.org/10.1177/0218492317736448
  16. Karimov JH, Bevilacqua S, Solinas M, Glauber M. Triple heart valve surgery through a right antero-lateral minithoracotomy. Interact Cardiovasc Thorac Surg. 2009;9(2):360-362. https://doi.org/10.1510/icvts.2009.206227
Published
2024-12-27
How to Cite
1.
Gurtovenko OM, Popov VV, Mazur AP, Bolshak OO. Myocardial Protection in Combined Mitral-Aortic-Tricuspid Valve Diseases Correction under Cardiopulmonary Bypass. ujcvs [Internet]. 2024Dec.27 [cited 2025Jan.2];32(4):91-5. Available from: https://cvs.org.ua/index.php/ujcvs/article/view/690
Issue
Ukrainian Journal of Cardiovascular Surgery Vol 32 No 4 2024
Section
ACQUIRED HEART DISEASES

Most read articles by the same author(s)